SLP

Simulations PlusB

Nasdaq / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$20.00

+19.3% vs current

Most likely

Base case

45%

Probability

Target price

$16.50

-1.6% vs current

B-

Bear case

25%

Probability

Target price

$11.50

-31.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-28

AI commentary

Recent headline flow is constructive: April 9 earnings emphasized revenue and margin improvement, and April 21 added a credible regulatory-adjacent collaboration. Still, the evidence base is mainly company-sourced and low coverage limits external confirmation, so sentiment should be treated as cautiously positive rather than broadly validated.

RankAlpha Sentiment Codex - 2026-04-28

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-27eventQ2 FY2026 results showed better mix and margins despite EPS guidance reset [#8-K-2026-04-09]High impact

The April 9 earnings release reported Q2 revenue up 8% to $24.3M, gross margin up to 66%, and adjusted EBITDA margin of 36%, while full-year revenue guidance stayed at $79M-$82M and adjusted EBITDA margin stayed at 26%-30%; only adjusted diluted EPS guidance was reduced to $0.75-$0.85 because the expected tax rate rose to 23%-25%.

2026-07-27catalystBacklog growth and software renewal activity can support second-half execution [#8-K-2026-04-09]Medium impact

Management said services bookings were strong and backlog increased about 18%, while software growth was helped by discovery and development solutions, new logo additions, and client upsells. If that converts cleanly, it supports the monitoring thesis that first-half momentum can carry into coming quarters.

2027-04-28catalystFunded Lonza-FDA collaboration could deepen regulatory relevance of GastroPlus and IVIVE workflows [#PR-2026-04-21]High impact

On April 21, the company announced a funded collaboration with Lonza and the U.S. FDA to develop and validate predictive frameworks for amorphous solid dispersion products, with Simulations Plus leading IVIVE development using DDDPlus and GastroPlus. The strategic value is credibility and future adoption leverage, but revenue timing remains unclear.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-28 • Updated nightlySource: Internal modelMethodology